Which thyroid disorder—hypothyroidism or hyperthyroidism—causes osteoporosis?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: February 10, 2026View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Hyperthyroidism Causes Osteoporosis

Hyperthyroidism—not hypothyroidism—is the thyroid disorder that causes osteoporosis and increases fracture risk. This relationship is well-established in both overt and subclinical forms of hyperthyroidism, particularly affecting postmenopausal women 1, 2.

Mechanism of Bone Loss in Hyperthyroidism

Excess thyroid hormone accelerates bone turnover with predominant bone resorption over formation 2, 3. The thyroid hormone surplus enhances osteoclast-driven bone resorption, creating a high-bone turnover state that leads to secondary osteoporosis 4. This accelerated remodeling cycle results in net bone loss and decreased bone mineral density (BMD) 2.

Clinical Evidence for Hyperthyroidism and Fracture Risk

Overt Hyperthyroidism

  • Untreated severe hyperthyroidism significantly influences bone mass and increases the probability of high-turnover osteoporosis 2
  • Overt thyrotoxicosis increases fracture risk in most studies, particularly affecting hip and spine 1
  • Adults with thyrotoxicosis have an established increased risk of osteoporotic fractures 5

Subclinical Hyperthyroidism

  • Subclinical hyperthyroidism (low TSH with normal free thyroid hormones) decreases BMD and increases fracture risk, especially in postmenopausal women 2, 6
  • Two meta-analyses reported significant declines in BMD during prolonged subclinical hyperthyroidism, with exogenous subclinical hyperthyroidism causing significant BMD loss among postmenopausal women but not premenopausal women 1
  • One prospective study found increased risk of hip and spine fractures in levothyroxine-treated women older than 65 years with TSH ≤0.1 mIU/L 1
  • Endogenous subclinical hyperthyroidism also adversely affects BMD and is associated with fractures 4

Iatrogenic Hyperthyroidism

  • Long-term TSH-suppressive doses of levothyroxine (used for thyroid nodules or thyroid carcinoma) may decrease BMD and induce increased fracture risk 2
  • These effects are particularly pronounced in postmenopausal women but less evident in premenopausal women 2
  • Patients with chronically suppressed TSH should ensure adequate daily calcium (1200 mg/day) and vitamin D (1000 units/day) intake 7

Hypothyroidism and Bone Health

In contrast, hypothyroidism does not cause osteoporosis. Overt hypothyroidism actually lowers bone turnover by reducing both osteoclastic bone resorption and osteoblastic activity, which results in increased bone mineralization 2. At present, there are no clear data demonstrating any relationship between decreased BMD and hypothyroidism in adults 2. Hypothyroidism in children causes impaired skeletal maturation and mineralization, but adequate thyroid hormone replacement stimulates normal bone growth 4.

Treatment Implications

Restoration of euthyroid status reverses bone loss in most patients with overt or subclinical hyperthyroidism 4. Treatment of hyperthyroidism to normalize TSH preserves BMD, though normalization of bone turnover may be delayed up to 1 year 1. Two studies of endogenous subclinical hyperthyroidism in postmenopausal women demonstrated significant continued bone loss in untreated patients compared with bone stabilization in treated patients 1.

Special Populations at Highest Risk

Postmenopausal women with TSH suppression face the greatest osteoporosis risk 1, 2. Women over 65 years with TSH ≤0.1 mIU/L have markedly increased risk of hip and spine fractures 1, 8. For postmenopausal women receiving TSH suppression therapy for thyroid cancer, antiresorptive treatments may be indicated 4.

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Thyroid Hormone Diseases and Osteoporosis.

Journal of clinical medicine, 2020

Research

Thyroid Hormone Actions and Bone Remodeling - The Role of the Wnt Signaling Pathway.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2020

Research

[Impact of thyroid diseases on bone].

Der Internist, 2018

Guideline

Initial Treatment for Elevated TSH

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Guideline

Evaluation of Subclinical Hyperthyroidism

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2026

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.